How long should I take Ibrutinib?

If ibrutinib is well tolerated, disease progression is limited, and toxicities are not seen, it is usually used indefinitely. In some people, very good partial clinical responses may occur within three to six months. The most common adverse reactions (≥20%) in adult or pediatric patients with cGVHD are fatigue, anemia, bruising, diarrhea, thrombocytopenia, musculoskeletal pain, pyrexia, muscle spasms, stomatitis, bleeding, nausea, abdominal pain, pneumonia, and headache. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.